Aptahem

About Us

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan

Suzanne Kilany, CRD Aptahem

It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects

Luiza Jedlina, CSO Aptahem

Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out

Mikael Lindstam, CEO Aptahem

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

First cohort dosed in Aptahem’s FIH study

Thu, Dec 29, 2022 11:46 CET

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first cohort of healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study.The first HV subjects have now successfully been dosed and the first cohort is completed in the randomized, placebo-controlled Phase 1 study evaluating the safety and tolerability of intravenous Apta-1. After the follow-up visits of this first cohort, Apta-1 seems safe and well tolerated. Clinical Research Director Suzanne Kilany

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

First cohort dosed in Aptahem’s FIH study

Subscribe